Imquest Life Sciences News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Major players in the biosimilar lymphocyte modulator market are Pfizer, Biogen, Genentech, Novartis, and Celltrion. The global biosimilar lymphocyte...

Share this article Share this article FORT COLLINS, Colo., April 20, 2021 /PRNewswire/ -- Cytocom, Inc. (Cytocom), a leading biopharmaceutical company creating next generation immune therapies built around proprietary discovery and development technologies, today announced that Stephen Wilson, Ph.D., has joined the company as its Head of Global Innovations, effective April 19, 2021. Dr. Wilson arrives at Cytocom after spending nearly 25 years at the La Jolla Institute for Immunology (LJII) where he was active in biomedical research and served as the research facility's chief operating offi...

FORT COLLINS — A small pharmaceutical company that recently relocated to Fort Collins is betting that an anti-addiction medicine that’s been around for decades could be repurposed to fight COVID, cancer and spur a new wave of immunity-focused treatments. In a matter of months, Cytocom Inc. went from a startup with a stalled research portfolio into a company that is soon to become Northern Colorado’s newest public company through a reverse merger and with four conditions that its drug candidate is ready to begin pivotal Phase III trials. The company is helmed by CEO Mike Handley, a Color...

Cleveland BioLabs, Inc. Files Registration Statement on Form S-4 for Proposed Merger with Cytocom Inc. Combined public entity to develop and commercialize next-generation immune therapies that address unmet needs in oncology, infectious disease, inflammation and auto-immune-mediated conditions FORT COLLINS, CO and BUFFALO, NY / ACCESSWIRE / February 17, 2021 / Cleveland BioLabs, Inc. (NASDAQ:CBLI), an innovative biopharmaceutical company developing novel approaches to activate the immune system, filed a registration statement on Form S-4 (the "Registration Statement") with the U.S. Securitie...

Share this article Share this article ResearchAndMarkets.com's offering. Biosimilar Lymphocyte Modulator Global Market Report 2020-30: COVID-19 Growth and Change provides the strategists, marketers and senior management with the critical information they need to assess the global biosimilar lymphocyte modulator market. Major players in the biosimilar lymphocyte modulator market are Pfizer, Biogen, Genentech, Novartis and Celltrion. The global lymphocyte modulator market is expected to decline from $1.29 billion in 2019 to $1.21 billion in 2020 at a compound annual growth rate (CAGR) of -5.57%...